Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Robert, C; Schachter, J; Long, G; Arance, A; Grob, J; Mortier, L; Daud, A; Carlino, M; McNeil, C; Lotem, M; Larkin, J; Lorigan, Paul C; Neyns, B; Blank, C; Hamid, O; Mateus, C; Shapira-Frommer, R; Kosh, M; Zhou, H; Ibrahim, N; Ebbinghaus, S; Ribas, A

Affiliation

Univ Paris Sud, F-94805 Villejuif, France.

Issue Date

2015-06-25

Metadata

Show full item record

Abstract

The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma.

Citation

Pembrolizumab versus Ipilimumab in Advanced Melanoma. 2015, 372 (26):2521-32 N. Engl J Med

Journal

The New England Journal of Medicine

URI

http://hdl.handle.net/10541/565800

DOI

10.1056/NEJMoa1503093

PubMed ID

25891173

Type

Article

Language

ISSN

1533-4406

Collections

All Christie Publications